Bortezomib
- Strength
- 3.5 mg/1
- Form
- Injection, Powder, Lyophilized, For Solution
- Class
- Proteasome Inhibitor
Avenacy, LLC
Listed by Shilpa Medicare Limited
| Dosage form | Injection |
|---|---|
| Route | Intravenous, Subcutaneous |
| Drug class | Proteasome Inhibitor |
| Approval route | NDA — original brand approval |
| NDC code | 63759-3032 |
| FDA application | NDA212782 |
| RxNorm concept | 2608948 |
| Package sizes listed | 1 |
| Marketed since | September 2024 |
Same active ingredient, different manufacturer, strength or form. Products matching on both ingredient and strength are usually interchangeable — but confirm before switching, especially with modified-release forms.
Avenacy, LLC
Sagent Pharmaceuticals
Gland Pharma Limited
MAIA Pharmaceuticals, Inc.
Zydus Pharmaceuticals USA Inc.
Hikma Pharmaceuticals USA Inc.
Dr.Reddy's Laboratories, Inc.
Eugia US LLC
Information only, not medical advice. Nothing on this page indicates that a medication is safe or suitable for you. Speak to a prescriber or pharmacist before starting, stopping or switching any medicine.
Please don't share card details in chat.